TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07815067: Investigating the Effect of Post-dose Meal Timings and Water Volume at Dosing on the Pharmacokinetic Properties of Oral Zenagamtide in Participants With Overweight or Obesity

Sponsor: Novo Nordisk A/S · Phase: PHASE1 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 320 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$7,224,320

Rescue Site Savings

+$4,763,536

Unlock Full NCT07815067 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07815067 Rescue Dossier →